Possible Benefit Found for Betrixaban in Acutely Ill

This article originally appeared here.
Share this content:
Possible Benefit Found for Betrixaban in Acutely Ill
Possible Benefit Found for Betrixaban in Acutely Ill

TUESDAY, May 31, 2016 (HealthDay News) -- Betrixaban may be beneficial versus enoxaparin in acutely ill medical patients, according to a study published online May 27 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee, held from May 25 to 28 in Montpellier, France.

Alexander T. Cohen, M.D., from Guy's and St. Thomas' Hospitals in London, and colleagues randomized 7,513 patients who were hospitalized for acute medical illnesses to either subcutaneous enoxaparin plus oral betrixaban placebo or subcutaneous enoxaparin placebo plus oral betrixaban. Analyses were performed in three prespecified cohorts: patients with an elevated D-dimer level (cohort 1), patients with an elevated D-dimer level or an age of ≥75 years (cohort 2), and all enrolled patients (overall population cohort).

The researchers found that the primary efficacy outcome (a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism) occurred in 6.9 percent of patients receiving betrixaban and 8.5 percent receiving enoxaparin in cohort 1 (relative risk, 0.81; 95 percent confidence interval [CI], 0.65 to 1.00; P = 0.054). In cohort 2 and the overall population cohort the rates were 5.6 and 7.1 percent (relative risk, 0.80; 95 percent CI, 0.66 to 0.98; P = 0.03) and 5.3 and 7.0 percent (relative risk, 0.76; 95 percent CI, 0.63 to 0.92; P = 0.006), respectively.

"Prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts," the authors write.

Several authors were employees of Portola Pharmaceuticals, which manufactures betrixaban and funded the study.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

PSA Screening Rates Have Leveled Off in U.S.

PSA Screening Rates Have Leveled Off in U.S.

Decline followed recommendations from U.S. Preventive Services Task Force

Surgeon General Dismissed by Trump Administration

Surgeon General Dismissed by Trump Administration

Had served just over two years of his four-year term

Most Patients Willing to Provide Sexual Orientation Data

Most Patients Willing to Provide Sexual Orientation Data

However, emergency department providers expect most to refuse to provide the information

is free, fast, and customized just for you!

Already a member?

Sign In Now »